Tags

Type your tag names separated by a space and hit enter

In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae.
New Microbiol. 2020 Jul; 43(3):136-138.NM

Abstract

KPC-producing Klebsiella pneumonia (KPC-Kp) represents a major therapeutic challenge in critically ill patients. Ceftazidime-avibactam (CAZ-AVI) is a new effective drug against KPC-Kp but, due to emerging resistant strains during monotherapy, the association with a second antibiotic has been advocated. Therefore, intravenous fosfomycin may be a possible choice for combination therapy. The aim of this study was to evaluate the in vitro susceptibility of CAZ-AVI alone and in combination with fosfomycin and carbapenems against KPC-Kp clinical isolates by E-test method. The combination of CAZ-AVI with carbapenems showed synergistic activity, whereas with fosfomycin showed addictive activity, suggesting that fosfomycin may be a carbapenem-sparing strategy in antimicrobial stewardship programs.

Authors+Show Affiliations

Section of Microbiology, Interdisciplinary Department of Medicine (DIM), School of Medicine, University of Bari, Italy.Section of Microbiology, Interdisciplinary Department of Medicine (DIM), School of Medicine, University of Bari, Italy.Section of Microbiology, Interdisciplinary Department of Medicine (DIM), School of Medicine, University of Bari, Italy.Anesthesia and Intensive Care Unit, Department of Emergency and Organ Transplantation, University of Bari, Italy.Anesthesia and Intensive Care Unit, Department of Emergency and Organ Transplantation, University of Bari, Italy.Section of Microbiology, Interdisciplinary Department of Medicine (DIM), School of Medicine, University of Bari, Italy. UOC Microbiology and Virology, Azienda Ospedaliera-Universitaria Policlinico of Bari, Bari, Italy.Section of Microbiology, Interdisciplinary Department of Medicine (DIM), School of Medicine, University of Bari, Italy. UOC Microbiology and Virology, Azienda Ospedaliera-Universitaria Policlinico of Bari, Bari, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32596740

Citation

Romanelli, Federica, et al. "In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae." The New Microbiologica, vol. 43, no. 3, 2020, pp. 136-138.
Romanelli F, De Robertis A, Carone G, et al. In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae. New Microbiol. 2020;43(3):136-138.
Romanelli, F., De Robertis, A., Carone, G., Dalfino, L., Stufano, M., Del Prete, R., & Mosca, A. (2020). In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae. The New Microbiologica, 43(3), 136-138.
Romanelli F, et al. In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae. New Microbiol. 2020;43(3):136-138. PubMed PMID: 32596740.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae. AU - Romanelli,Federica, AU - De Robertis,Annalisa, AU - Carone,Gianluca, AU - Dalfino,Lidia, AU - Stufano,Monica, AU - Del Prete,Raffaele, AU - Mosca,Adriana, Y1 - 2020/06/29/ PY - 2020/09/04/received PY - 2020/09/04/accepted PY - 2020/7/1/pubmed PY - 2020/12/1/medline PY - 2020/6/30/entrez KW - KPC-producing Klebsiella pneumoniae KW - carbapenems KW - ceftazidime-avibactam KW - fosfomycin KW - synergy SP - 136 EP - 138 JF - The new microbiologica JO - New Microbiol VL - 43 IS - 3 N2 - KPC-producing Klebsiella pneumonia (KPC-Kp) represents a major therapeutic challenge in critically ill patients. Ceftazidime-avibactam (CAZ-AVI) is a new effective drug against KPC-Kp but, due to emerging resistant strains during monotherapy, the association with a second antibiotic has been advocated. Therefore, intravenous fosfomycin may be a possible choice for combination therapy. The aim of this study was to evaluate the in vitro susceptibility of CAZ-AVI alone and in combination with fosfomycin and carbapenems against KPC-Kp clinical isolates by E-test method. The combination of CAZ-AVI with carbapenems showed synergistic activity, whereas with fosfomycin showed addictive activity, suggesting that fosfomycin may be a carbapenem-sparing strategy in antimicrobial stewardship programs. SN - 1121-7138 UR - https://www.unboundmedicine.com/medline/citation/32596740/In_Vitro_Activity_of_Ceftazidime/Avibactam_Alone_and_in_Combination_With_Fosfomycin_and_Carbapenems_Against_KPC_producing_Klebsiella_Pneumoniae_ L2 - http://www.newmicrobiologica.org/PUB/allegati_pdf/2020/3/136.pdf DB - PRIME DP - Unbound Medicine ER -